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ABSTRACT
Objective To evaluate the proportion of patients
hospitalised with acute coronary syndrome (ACS) in
Australia and New Zealand who received optimal
inpatient preventive care and to identify factors
associated with preventive care.
Methods All patients hospitalised bi-nationally with
ACS were identiﬁed between 14–27 May 2012. Optimal
in-hospital preventive care was deﬁned as having
received lifestyle advice, referral to rehabilitation, and
prescription of secondary prevention pharmacotherapies.
Multilevel multivariable logistic regression was used to
determine factors associated with receipt of optimal
preventive care.
Results For the 2299 ACS survivors, mean (SD) age
was 69 (13) years, 46% were referred to rehabilitation,
65% were discharged on sufﬁcient preventive
medications, and 27% received optimal preventive care.
Diagnosis of ST elevation myocardial infarction (OR: 2.64
[95% CI: 1.88–3.71]; p<0.001) and non-ST elevation
myocardial infarction (OR: 1.99 [95% CI: 1.52–2.61];
p<0.001) compared with a diagnosis of unstable
angina, having a percutaneous coronary intervention
(PCI) (OR: 4.71 [95% CI: 3.67–6.11]; p<0.001) or
coronary bypass (OR: 2.10 [95% CI: 1.21–3.60];
p=0.011) during the admission or history of
hypertension (OR:1.36 [95% CI: 1.06–1.75]; p=0.017)
were associated with greater exposure to preventive care.
Age over 70 years (OR:0.53 [95% CI: 0.35–0.79];
p=0.002) or admission to a private hospital (OR:0.59
[95% CI: 0.42–0.84]; p=0.003) were associated with
lower exposure to preventive care.
Conclusions Only one-quarter of ACS patients received
optimal secondary prevention in-hospital. Patients with
UA, who did not have PCI, were over 70 years or were
admitted to a private hospital, were less likely to receive
optimal care.
BACKGROUND
Cardiovascular disease (CVD), including coronary
heart disease (CHD) and stroke, is the leading
cause of death and disease burden globally.1 In
Australia, CHD accounts for the greatest disease
morbidity and nearly one ﬁfth of all deaths nation-
ally.2 The potentially life-threatening presentation
with CHD is a spectrum of clinical conditions
known as acute coronary syndrome (ACS) which
includes ST segment elevation myocardial infarction
(STEMI), non-ST segment elevation MI (NSTEMI),
and unstable angina (UA).3 Importantly, approxi-
mately half of these events occur in individuals
who have had a prior hospital admission for
CHD.3–5 European,6 7 American,8 and Australian3
guidelines routinely recommend strategies aimed at
preventive care, preferably commencing while the
patient is in hospital. These guidelines emphasise
the importance of secondary prevention pharmaco-
therapy, lifestyle advice, and participation in a
cardiac rehabilitation or secondary prevention
programme.
Cross-sectional surveys and registries are a valu-
able means for assessing the implementation of
guidelines.9–11 Indeed, international registries have
demonstrated suboptimal pharmacotherapy and
referral to cardiac rehabilitation at discharge across
various settings.9–11 The ﬁrst Euro Heart Survey of
ACS, conducted in 25 countries in Europe and the
Mediterranean basin in 2000–2001, demonstrated
substantial variability in the implementation of
guidelines applicable at that time.12 A second Euro
Heart Survey in 2004 among 32 countries, which
aimed to reassess ACS management and implemen-
tation of more contemporary guidelines, showed
persistent gaps in chronic care.10 New Zealand
researchers have also demonstrated low levels of
investigations, appropriate pharmacotherapy treat-
ments, and acute revascularisation in previous
audits of ACS care in 2002 and 2007.13 14
ACS registries have provided valuable informa-
tion about treatment and resource gaps15; however,
they frequently include relatively few patients from
regional and remote centres.4 In addition, very few
registries have reported on the synergistic impact of
comprehensive care comprising medications, life-
style advice, and post-discharge preventive activ-
ities. This is particularly important given there is
evidence that medications started in hospital are
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more likely to be continued16 and recent ﬁndings that early
referral to cardiac rehabilitation improves later attendance at
programme orientation.17 The inclusion of all consenting acute
medical services in Australia and New Zealand providing imme-
diate care to patients presenting with suspected ACS allows a
unique opportunity to collect a complete perspective on pat-
terns of ACS care across both countries. This paper evaluates
the proportion of patients admitted to an Australian or New
Zealand hospital with ACS, surviving to discharge, who received
optimal in-hospital preventive care (comprising medications,
lifestyle advice, and referral to rehabilitation). We also aimed to
identify important clinical factors that were associated with
exposure to optimal preventive care during an ACS admission.
METHODS
Study design
The SNAPSHOT ACS study was a prospective audit of the care
provided to consecutive patients admitted to an Australian or
New Zealand hospital with suspected ACS during a speciﬁed
2-week period.15 The study was designed by a bi-national aca-
demic network of clinicians and researchers and was managed
by a steering committee with key stakeholder representation. An
overview of the ﬁndings is published elsewhere.15 This present
article speciﬁcally focuses on preventive care at the point of dis-
charge and provides a detailed analysis only of those patients
who survived their index admission and had a conﬁrmed diag-
nosis of STEMI, NSTEMI or UA. Written study protocols were
provided to all sites and relevant research staff were given train-
ing and support for data collection and entry. Ethical approval
(with opt-out consent) was obtained for Australian sites and
single review (with consent waiver) in New Zealand’s case was
obtained from all participating sites.
Sites and participants
All hospitals receiving patients with suspected ACS (including
public or private, metropolitan or rural) were identiﬁed from
public records and invited to participate. Patients were eligible if
they were admitted with a suspected or conﬁrmed ACS event
between 14 May 00:00 h and 27 May 24:00 h, 2012.15
Consecutive admissions were enrolled and patients were fol-
lowed for the duration of the acute care episode, including all
contiguous transfers between hospitals (counted as a single
episode of care).
Data collection
A common case report form, with standardised completion
note, was developed by opinion leaders in collaboration with a
multidisciplinary team comprising allied health professionals,
biostatisticians, epidemiologists, and data management consul-
tants and trialled across multiple jurisdictions in approximately
60 patients. Data collection was from medical records and
focused on presenting characteristics, including clinical variables
enabling the calculation of the Global Registry of Acute
Coronary Events (GRACE) risk score,18 as well as details of
patient presentation and transfers between hospitals. Data
missing from medical records was record as ‘no’. Utilisation of
guideline recommended therapies including inpatient invasive
management/revascularisation, dietary/physical activity advice,
and prior-to-discharge prescription of aspirin, other oral antipla-
telet therapies, statin, β-blocker, ACE inhibitor (ACEi) or angio-
tensin receptor blocker (ARB), and referral for cardiac
rehabilitation were all assessed. Smoking cessation advice was
reported separately. Data were collected using a customised
database permitting secure, web-based entry of each patient.
Exposure to preventive care
To quantify exposure to preventive care we devised a composite
outcome based on a series of standard variables derived from inter-
national guidelines.3 6–8 In combination these guidelines identify
three important areas for ongoing preventive care, namely
pharmacotherapy, lifestyle advice/change, and cardiac rehabilita-
tion. It is for this reason that we deﬁned optimal preventive care as
the patient having received at least one aspect of lifestyle advice
in-hospital (exercise or diet advice and quit advice for smokers),
referral to cardiac rehabilitation post-discharge, and prescription
of at least four of the ﬁve major preventive pharmacotherapies
(lipid lowering, aspirin, other antiplatelet, β-blocker, or ACEi/
ARB). This was slightly different for patients with UA and a
GRACE risk score <130, where prescription of at least two pre-
ventive pharmacotherapies (namely aspirin and statin) was used to
quantify exposure to preventive care.7 Given that the relative con-
tributions of medication, referral to rehabilitation, and lifestyle
advice may not be equivalent in terms of outcomes, we also con-
ducted an additional analysis with extra weighting for medications.
For this analysis, 50% weighting was assigned to pharmacotherapy
and 50% weighting was assigned to rehabilitation/risk factor
advice, as is consistent with evidence for their relative contribution
in reducing CHD mortality.19 20
Statistical analysis
Patient characteristics, rates of referral to cardiac rehabilitation,
provision of guideline recommended medications, and access to
inpatient preventive care are presented using standard descriptive
statistics stratiﬁed by discharge diagnosis. Categorical variables are
reported as numbers and percentages (compared using χ2 test) and
continuous variables as means and SD or medians and IQRs. We
used multilevel multivariable logistic regression models (Proc
Glimmix) in all analyses to derive the ORs and corresponding
95% CIs, where the effect of clustering by hospital was modelled
as a random intercept. We identiﬁed input variables that were
likely to be of clinical importance; these were: age, gender, dis-
charge diagnosis (STEMI, NSTEMI, UA), current smoker, percu-
taneous coronary intervention (PCI) during index admission,
coronary artery bypass graft surgery (CABG) during index admis-
sion, prior PCI or CABG, prior vascular disease (including prior
myocardial infarction, peripheral arterial disease, transient ischae-
mic attack or stroke), history of diabetes mellitus, history of hyper-
tension, history of morbid obesity, and length of index ACS stay
(days). Public versus private hospital was the second level predictor
variable. In all models, covariates were mutually adjusted and ana-
lyses were undertaken using Statistical Analysis Software (SAS)
Enterprise Guide 4.3. A value of p<0.05 was considered statistic-
ally signiﬁcant for all analyses.
RESULTS
The main SNAPSHOTACS results, including state and population
data, have been reported previously.14 In summary, 4398 patients
with suspected or conﬁrmed ACS were identiﬁed from a potential
pool of 525 hospitals across Australia and New Zealand.14 Some
483 hospitals (92% of all potential hospitals) gained ethics
approval, 444 in Australia (with opt-out consent) and 39 in New
Zealand (national consent). In total, 286 sites contributed to
recruitment with the 197 non-enrolling hospitals being smaller,
outside larger population centres, and not treating patients with
suspected ACS during the 2-week audit window.14 Every effort
was made to ensure recruitment into the study was maximised
with an opt-out consent for all but two hospitals (only 44 potential
participants chose to opt-out) and through daily cross-checking
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with hospital admissions databases during the study period. A
total of 83 patients from the original cohort died in-hospital, and
a further 2016 had a discharge diagnosis of non-ischaemic chest
pain and are not included in this analysis of exposure to preventive
care. The risk proﬁle of the ACS cohort (n=2299) was high (mean
GRACE score 128±31). As expected, the GRACE risk score was
higher in those with STEMI (138±31) and NSTEMI (135±31)
than in those with UA (116±28).
Patient characteristics and preventive care at discharge
Table 1 summarises the characteristics and clinical details for sur-
viving patients with a diagnosis of ACS (n=2299). Of those who
experienced an ACS event (STEMI, NSTEMI, UA) (n=2299),
two-thirds were male, 53% had a total cholesterol value
≥4.5 mmol/L, 49% had a blood glucose value ≥6.5 mmol/L, 53%
had a systolic blood pressure ≥140 mmHg, and 19% were docu-
mented as being current smokers. In terms of inpatient preventive
care, approximately two-thirds of smokers received quit advice,
only 10% were screened for depression, 36% received inpatient
dietary advice, and 43% received physical activity advice. Among
Indigenous ACS patients, only 54% (66/122) were seen by an
Indigenous Health Worker during their admission.
At discharge, 46% of all ACS patients were referred to an
outpatient cardiac rehabilitation programme. Documented
Table 1 Demographic, clinical and discharge care
STEMI (n=390) NSTEMI (n=981) UA+chest pain of likely ischaemic origin (n=928) All ACS (n=2299)
Demographics and documented medical history before index admission*
Mean age, years (SD) 65 (14) 71 (13) 68 (13) 69 (13)
Male 283 (73) 619 (63) 586 (63) 1488 (65)
Prior MI 64 (16) 330 (34) 334 (36) 728 (32)
Prior PCI 44 (11) 180 (18) 308 (33) 532 (23)
Prior CABG 16 (4) 129 (13) 133 (14) 278 (12)
History of hypertension 209 (54) 673 (69) 676 (73) 1558 (68)
History of hyperlipidaemia 176 (45) 571 (58) 617 (66) 1364 (59)
Diabetes 69 (18) 303 (31) 288 (31) 660 (29)
Prior PAD or TIA or stroke 31 (8) 197 (20) 149 (16) 377 (16)
Morbid obesity (≥35 kg/m2) 21 (5) 81 (8) 77 (8) 179 (8)
Other comorbidity† 40 (10) 219 (22) 155 (17) 414 (18)
Length of stay for index admission, median days (IQR) 4.1 (2.9, 6.5) 4.2 (2.9, 6.8) 2.1 (1.1, 4.1) 3.5 (2.0, 5.8)
Documented clinical measures during index admission*
Total cholesterol, mean (SD) 4.78 (1.2) 4.68 (1.4) 4.57 (1.3) 4.67 (1.3)
≥4.5 mmol/L 179/306 (58) 317/605 (52) 215/438 (49) 711/1349 (53)
LDL cholesterol, mean (SD) 2.89 (1.0) 2.74 (1.1) 2.51 (1.2) 2.7 (1.1)
≥2.5 mmol/L 174/265 (66) 290/519 (56) 155/326 (48) 619/1110 (56)
Glucose, mean (SD) 8.55 (5.5) 9.40 (12.8) 8.11 (8.8) 8.74 (10.3)
≥6.5 mmol/L 204/324 (63) 389/741 (52) 261/665 (39) 854/1730 (49)
Systolic blood pressure, mean (SD) 136.1 (26.4) 144.7 (28.0) 144.4 (26.0) 143.1 (27.1)
≥140 mm Hg 162/385 (42) 541/973 (56) 516/924 (56) 1219/2282 (53)
Current smoker 125 (32) 174 (18) 134 (14) 433 (19)
Revascularisation during admission 295 (76) 414 (42) 175 (19) 884 (38)
GRACE risk score 138 (31) 135 (31) 116 (28) 128 (31)
Documented preventive care received during index admission*
Smoking cessation advice/current smokers 103/125 (82) 118/174 (68) 80/134 (60) 301/433 (70)
Screening for depression 50 (13) 115 (12) 63 (7) 228 (10)
Dietary modification advice 208 (53) 408 (42) 215 (23) 831 (36)
Physical activity advice 247 (63) 491 (50) 250 (27) 988 (43)
Inpatient cardiac rehabilitation 235 (60) 470 (48) 257 (28) 962 (43)
Seen by Indigenous health worker/Indigenous‡ 13/22 (59) 27/51 (53) 26/49 (53) 66/122 (54)
Referral to outpatient cardiac rehabilitation 277 (71) 525 (54) 263 (28) 1065 (46)
Medications prescribed at discharge*
Aspirin 376 (96) 860 (88) 770 (83) 2006 (87)
Other antiplatelet 335 (86) 696 (71) 420 (45) 1451 (63)
Statin/other lipid lowering therapy 361 (93) 843 (86) 740 (80) 1944 (85)
β-blocker 319 (82) 749 (76) 572 (62) 1640 (71)
ACEi or A2RB 296 (76) 649 (66) 561 (60) 1506 (65)
Diabetic drug§ 62 (17) 242 (27) 231 (28) 535 (23)
Antidepressant 43 (12) 124 (14) 177 (22) 344 (15)
*n(%), unless otherwise specified.
†Other comorbidity includes—cancer, liver disease, dementia, renal impairment or on dialysis.
‡Includes all those documented as being of Aboriginal/Torres Strait/Maori/Pacific Island background.
§Diabetic drug includes metformin, insulin, and other diabetic drug.
A2RB, angiotensin II receptor blocker; ACEi, ACE inhibitor; ACS, acute coronary syndrome; CABG, coronary artery bypass graft surgery; GRACE, Global Registry of Acute Coronary Events;
LDL, low density lipoprotein cholesterol; MI, myocardial infarction; NSTEMI, non-ST segment elevation myocardial infarction; PAD, peripheral arterial disease; PCI, percutaneous coronary
intervention; SBP, systolic blood pressure; STEMI, ST segment elevation myocardial infarction; TC, total cholesterol; TIA, transient ischaemic attack; UA, unstable angina.
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prescription rates of guideline recommended medicines for ACS
(lipid lowering, aspirin, antiplatelet, β-blocker, ACEi/ARB) at
discharge were 4–5 (1490/2299, 65%) or 2–3 (632/2299,
27%), and 4% of patients were documented as having not been
prescribed any pharmacotherapy. Of the patients with UA, 32%
(299/928) had a GRACE risk score ≥130, 68% (629/928) had a
GRACE risk score <130, and 50% (468/928) had experienced
prior MI or had undergone PCI or CABG.
Exposure to optimal preventive care
Table 2 summarises the proportion of ACS patients who
received optimal preventive care during their admission. In
total, only 27% of patients received at least four medications
(or two in the case of those with UA and a GRACE risk score
<130), dietary or physical activity advice, and referral to
cardiac rehabilitation. Rates of optimal care were highest among
STEMI patients (51%) and signiﬁcantly lower for NSTEMI
patients (30%, p<0.001) and patients with UA (15%,
p<0.001). When additional emphasis was given to medication
prescription (50% weighting for medicines and 50% for lifestyle
advice and rehabilitation), 45% (1041/2299) of the cohort were
exposed to optimal care (medication prescription and lifestyle
advice or rehabilitation referral).
Factors associated with exposure to optimal preventive care
The adjusted ORs and CIs describing the likelihood of receiving
the various components of preventive care at the time of dis-
charge are presented in ﬁgure 1. Factors associated with greater
likelihood of being discharged with appropriate medications (at
least four secondary prevention medications except in the case
of UA patients with GRACE risk <130 where lipid lowering
and aspirin alone were required) were: having a diagnosis of
STEMI (p=0.001) or NSTEMI (p=0.021), undergoing PCI
(p<0.001) during the index admission, having had PCI or
CABG before the index admission (p<0.001), and having a
history of prior hypertension (p=0.005). Factors associated
with greater likelihood of referral to cardiac rehabilitation were:
having a diagnosis of STEMI (p<0.001) or NSTEMI
(p<0.001), having PCI (p<0.001) or CABG (p<0.001) during
the index admission, or having a history of hypertension
(p=0.035). Being of older age (p<0.001) and being admitted
to a private hospital (p=0.004) were associated with less likeli-
hood of referral to rehabilitation. Factors associated with greater
likelihood of provision of inpatient lifestyle advice while
in-hospital were: diagnosis of STEMI (p<0.001) or NSTEMI
(p<0.001), having PCI (p<0.001) or CABG (p<0.006) during
the index admission, being obese (p=0.042), and having a
shorter length of stay (p<0.001). Being older than 70 years
(p=0.012) was associated with lower likelihood of receiving
inpatient lifestyle advice.
The adjusted ORs and CIs describing the likelihood of receiv-
ing optimal preventive care during the admission are presented
in ﬁgure 2. Patients with a diagnosis of STEMI (p<0.0001) or
NSTEMI (p<0.0001), who had PCI (p<0.0001) or CABG
(p=0.011) during the index admission, or who had a history of
hypertension before the index admission (p=0.017) were more
likely to receive optimal care. Patients aged over 70 years
(p=0.002) and those admitted to a private hospital (p=0.003)
were less likely to receive optimal care.
DISCUSSION
This cohort study provides a unique and comprehensive ‘snap-
shot’ of the preventive care delivered to 2299 patients admitted
to Australian and New Zealand hospitals (public and private)
with conﬁrmed ACS at discharge. Despite universal guideline
recommendations, around three-quarters of all patients admitted
with ACS did not receive basic preventive care comprising
proven pharmacotherapy, lifestyle advice, and referral to
rehabilitation. Importantly, we classiﬁed receipt of lifestyle
advice as any documented evidence of receipt of any form of
dietary or physical activity advice, which is a very low bar in
terms of individualised advice, and therefore it is highly likely
that even fewer patients received individualised advice from
appropriate health professionals. Further, the rate was still less
than half when greater weighting was given to medication pre-
scription. We also found that older age, diagnosis of UA, not
having PCI, and being admitted to a private hospital were asso-
ciated with lower likelihood of receiving optimal care.
Therefore, this study not only highlights the clear variation in
provision of preventive care across the ACS diagnosis spectrum,
but also provides more detailed information about where oppor-
tunities exist to improve delivery of care.
International guidelines recommend that all patients with
ACS should be referred to cardiac rehabilitation (CR), provided
with basic lifestyle advice, and prescribed preventive pharmaco-
therapy.3 6–8 In this study, only one-quarter of the cohort
received this level of preventive care. In addition, Australian and
other international guidelines recommend all patients should be
screened for depression.3 We found that this only occurred in
10% of the ACS population. Further, only about half of the
patients of Indigenous background were reviewed by an
Indigenous health-worker during their hospital stay. This study
found that 46% of ACS patients were referred to cardiac
rehabilitation, but a 2010 report (n=1545) by the National
Prescribing Service of Australia found that even when patients
were referred to cardiac rehabilitation, only half completed the
programme.21 These ﬁndings are concerning and call for urgent
Table 2 Exposure to preventive care during ACS admission
Guideline recommendation* STEMI NSTEMI UA All ACS
Discharged on secondary prevention medications† 330/390 (85) 697/981 (71) 603/928 (65) 1630/2299 (71)
Inpatient advice about smoking cessation if a smoker 103/125 (82) 118/174 (68) 80/134 (60) 301/433 (69)
At least 1 of diet or physical activity advice received 259/390 (66) 521/981 (53) 279/928 (30) 1059/2299 (46)
Received referral to outpatient cardiac rehabilitation 277/390 (71) 525/981 (53) 263/928 (28) 1065/2299 (46)
Total (medicines+lifestyle advice+referral to cardiac rehabilitation) 197/390 (51) 296/981 (30) 135/928 (15) 628/2299 (27)
*n(%), unless otherwise specified.
†Based on any four of the following—aspirin, other antiplatelet, statin or lipid-lowering agent, β-blocker or angiotensin II receptor blocker/ACE inhibitor except in the case of patients
with UA and GRACE risk score <130 where at least prescription of aspirin and lipid lowering was required.
ACS, acute coronary syndrome; GRACE, Global Registry of Acute Coronary Events; NSTEMI, non-ST segment elevation myocardial infarction; STEMI, ST segment elevation myocardial
infarction; UA, unstable angina.
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review and consideration of preventive care for patients with
ACS bi-nationally. Optimising patient outcomes after ACS
through standardisation of care has now emerged as a major
near-term goal in the health agenda of Australia and New
Zealand.22 This present study highlights the importance of
inclusion of preventive care aspects within that agenda.
Our results are similar to other international studies. Two
large prospective surveys of ACS patients across numerous
European countries have shown similar rates of pharmacother-
apy to the Australian and New Zealand SNAPSHOT Registry.10
In the more recent European audit (n=6385) compared to the
bi-national SNAPSHOT, rates of aspirin were similar for STEMI
(97% vs 96%) and NSTEMI (94% vs 88%). Corresponding
results for statins were STEMI (81% vs 93%) and NSTEMI
(74% vs 86%), and for ACEi/ARB were STEMI (75% vs 76%)
and NSTEMI (69% vs 66%).10 Our results for
Figure 1 Adjusted ORs and 95% CIs* for likelihood of receiving at least four secondary prevention medicines on discharge, referral to cardiac
rehabilitation, and inpatient lifestyle advice (OR >1 means likely). *Using multilevel multivariable logistic regression. **Based on any four of the
following—aspirin, other antiplatelet, statin or lipid lowering agent, β-blocker or angiotensin II receptor blocker/ACE inhibitor except in the case of
patients with unstable angina and GRACE risk score <130 where at least prescription of aspirin and lipid lowering was required. CABG, coronary
artery bypass graft surgery; GRACE, Global Registry of Acute Coronary Events; MI, myocardial infarction; NSTEMI, non-ST segment elevation
myocardial infarction; PAD, peripheral arterial disease; PCI, percutaneous coronary intervention; STEMI, ST segment elevation myocardial infarction;
TIA, transient ischaemic attack; UAP, unstable angina pectoris.
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pharmacotherapy are also very similar to those reported by the
American CRUSADE (n=64 426) national quality improvement
initiative.23 Recent results of the Myocardial Ischaemia National
Audit Project (MINAP) based in the UK report medication pre-
scription of over 95%, which is clearly higher than our
Australian/New Zealand results; however, the MINAP cohort
excludes patients who have been transferred, who have contra-
indications or who choose not to take medicines.24 In New
Zealand, two previous ACS audits have also been crucial in
deﬁning treatment and resource gaps in that country over recent
years.13 14 In the 2002 New Zealand audit of 695 discharged
(alive) ACS patients and the 2007 New Zealand audit of 815
discharged ACS patients, the use of discharge medications was
also generally lower than in the present study including aspirin
(82% and 82%, vs 87%), β-adrenergic blockers (63% and 66%,
vs 71%), and statins (55% and 70%, vs 85%). These New
Zealand audits are now 5 and 10 years old and improvements
in prescription of discharge pharmacotherapy, especially statin
therapy, may have occurred. While our study shows similar rates
of pharmacotherapy, very few of the previous audits have
reported inpatient preventive lifestyle care and referral to
rehabilitation in the same cohort.
Clinical diagnosis and PCI during the index admission were
consistently associated with improved preventive care. Patients
diagnosed with MI (STEMI or NSTEMI) were signiﬁcantly more
likely to receive secondary prevention pharmacotherapy, referral
to rehabilitation, and inpatient lifestyle advice. Interestingly,
older patients and those admitted to private hospitals were less
likely to receive optimal preventive care. These differences could
potentially be explained by shorter mean length of stay and
potentially poorer documentation for patients admitted to the
private hospitals, although this possibility requires further inves-
tigation. Unsurprisingly, those who had a longer hospital stay
were more likely to receive inpatient dietary and physical activity
advice, and those with obesity were more likely to receive
inpatient dietary advice. This variability, particularly in relation
to diagnosis, highlights the need for a more considered approach
to the prevention of disease recurrence. Encouragingly, we con-
ﬁrmed that those with prior hypertension, prior vascular disease
and PCI were more likely to receive secondary prevention
pharmacotherapy.
The results of this study highlight extensive inequality in
terms of the delivery of preventive care at a most vital time–the
hospital admission. In particular diagnosis, intervention, age,
and hospital type all impacted on the preventive care that
patients received. Understanding why these inequities occur may
help improve our health systems. The observations suggest that
the practice patterns may reﬂect ‘value judgements’ where there
may be a greater appreciation of value in the younger and
STEMI patients. Documented risk stratiﬁcation and discharge
care planning may help overcome the perceived ‘judgement’
approach to provision of care. In addition, the development of
standardised performance measures (for implementation in
private and public hospitals) relating to secondary prevention
are likely to be critical in providing objective evidence that
optimal preventive care was provided. Such clinical standards
and performance measures would need to take into account the
diagnostic and therapeutic complexities for each patient.15
Figure 2 Adjusted ORs and 95% CIs* for likelihood of provision of optimal preventive care (OR >1 means more likely). *Using multilevel
multivariable logistic regression. CABG, coronary artery bypass graft surgery; MI, myocardial infarction; NSTEMI, non-ST segment elevation
myocardial infarction; PAD, peripheral arterial disease; PCI, percutaneous coronary intervention; STEMI, ST segment elevation myocardial infarction;
TIA, transient ischaemic attack; UAP, unstable angina pectoris.
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The strengths of this study are the inclusive nature of its design.
This study is unique in its ability to provide insights into the provi-
sion of care but it is limited by the nature of data collection, namely,
via analysis of the medical records. The design allows widespread
and valuable benchmarking at a single time point rather than local
continuous quality improvement to monitor change over time. This
study highlights that valuable health system and public health
insights can be obtained from a ‘snapshot in time’ at potentially
much lower costs than large scale and ongoing audits. Further,
although we have deﬁned optimal care as having received inpatient
lifestyle advice, medications and referral to rehabilitation on dis-
charge, we are unable to determine the speciﬁc relative contribu-
tions of each of these aspects of care; future research is needed to
investigate the ratio that each of these interventions may play in
terms of future hospital readmissions and mortality.
This study is not without limitations. Most importantly, this
was an audit project (without clinical outcomes) and reports
data collected from medical records. As with any observational
dataset, results need to be considered in the context of potential
variation in record keeping between and within centres and
issues of attribution, given that local researchers collected data
within their area of employment. Also, data were collected
based on hospital admissions during a 2-week period; this may
not be representative of admissions over the entire calendar year
and it may not be reﬂective of actions (eg, completion of
rehabilitation) actually taken by patients after discharge. In add-
ition, when analysing prescription of pharmacotherapy (despite
the case report form allowing for removal of cases where medi-
cations were contraindicated or where there was drug intoler-
ance/resistance) in a study such as this, it is difﬁcult to account
for the entirety of heterogeneity that exists between patients,
particularly in those with UA. Although we have used the
GRACE risk score as an indicator of risk, results should be
considered with this in mind. Finally, the study reports the pre-
ventive care received during the index admission, and data per-
taining to what happens after the patients leave hospital is an
area that requires ongoing research.
CONCLUSIONS
Only one-quarter of all patients admitted with ACS received
optimal secondary prevention (pharmacotherapy, lifestyle advice,
and referral to rehabilitation). This study provides unique insights
into the provision of preventive therapy and lifestyle modiﬁcation
advice (or lack thereof) to patients admitted to hospital with an
ACS. Proportionately more STEMI than non-STEMI and UA
patients received guideline recommended preventive care.
Findings also suggest that younger patients, those who have a PCI
during admission, and those admitted to public hospitals are more
likely to receive optimal preventive care. These ﬁndings highlight
the persistence of the evidence treatment gaps in a contemporary
cohort of ACS patients. Standardising inpatient care in line with
guidelines is likely to contribute to more effective secondary pre-
vention post-discharge.
Author afﬁliations
1The George Institute for Global Health, Sydney, Australia
2 Sydney Medical School, University of Sydney, Sydney, Australia
3Department of Cardiovascular Medicine, Flinders University, Southern Adelaide
Local Health Network, Adelaide, Australia
4Statewide Cardiac Clinical Network, South Australian Health; Flinders University,
Adelaide, Australia
5Westmead Hospital, Sydney, Australia
6Cardiology Department, Concord Hospital, Sydney, Australia
7Queensland Health, Brisbane, Australia
8Cardiac Network, Agency for Clinical Innovation, Sydney, Australia
9National Heart Foundation of Australia (New South Wales Division) Sydney,
Australia
10Royal Brisbane Hospital, Brisbane, Australia
11Green Lane CVS Service, Auckland City Hospital, Auckland, New Zealand
12Liverpool Hospital Sydney, Australia
13University of New South Wales, Sydney Australia
14School of Population Health, University of Western Australia, Perth, Australia
Acknowledgements Steering Committee: David Brieger (NSW), Co-chair, John
French (NSW) Co-chair, Derek Chew (SA) Co-chair, Chris Ellis (NZ), Co-Chair, Gerry
Devlin (NZ), Co-Chair, Chris Hammett (QLD), Bernadette Aliprandi-Costa (NSW), Isuru
Ranasinghe (NSW), Bridie Carr (NSW), Julie Redfern (NSW), Fiona Turnbull (NSW),
Carolyn Astley (SA), Tom Briffa (WA), Jamie Rankin (WA), Ahmad Farshid (ACT), Pearl
Taverner (ACT), Darren Walters (QLD), Stephen Bloomer (WA), John Elliott (NZ), Jeff
Lefkovits (Vic), Karice Hyun (NSW). Project managers- State-based Cardiac Clinical
networks. New Zealand- Greg Gamble, NSW/ACT- Bernadette Aliprandi-Costa, Bridie
Carr, Karen Lintern, Pearl Taverner, Queensland- Tegwen Howell, Cindy Hall, Susanne
Spencer, Dayna Williamson, Victoria- Hella Parker, Julie Plunkett, Wendy
Wallace-Mitchell, South Australia, TAS, NT- Rosanna Tavella, Carolyn Astley, Western
Australia- Samantha Thompson. Data Management and analysis- The George Institute
for Global Health and the South Australian Health and Medical Research Institute
(SAHMRI): Associate Professor Fiona Turnbull, Dr Isuru Ranasinghe, Associate Professor
Julie Redfern, Karice Hyun, Matthew Horsfall, Helen Hughes.
Contributors All authors have been involved in the study from inception and have
approved the ﬁnal manuscript.
Funding The SNAPSHOT ACS study was supported in part by: The Cardiac Society
of Australia and New Zealand; The National Heart Foundation of Australia, The
Agency for Clinical Innovation (NSW), the Victorian Cardiac Clinical Network,
the Queensland Cardiac Clinical Network, the Cardiovascular Health Network,
Department of Health, WA and the State-wide Cardiac Clinical Network, South
Australian Health. The study was endorsed by the Australian Commission for Quality
and Safety in Health Care and supported with in-kind support from each of the
participating hospitals and their respective State and Territory Departments of
Health. JR is funded by a NHMRC Career Development Fellowship (APP1061793)
co-funded with a National Heart Foundation Future Fellowship (G160523). CC is
funded by a Career Development Fellowship co-funded by the NHMRC and National
Heart Foundation of Australia (1033478) and Sydney Medical Foundation Chapman
Fellowship. FT is supported by a National Heart Foundation of Australia Career
Development Award.
Key messages
What is already known about this subject?
▸ Approximately half of acute coronary events occur in
individuals with prior disease.
▸ Internationally, acute coronary syndrome (ACS) guidelines
recommend strategies targeting preventive care and
highlight the importance of commencing preventive care
immediately after ACS.
What does this study add?
▸ Provision of preventive care in patients admitted to hospital
with ACS is suboptimal.
▸ Proportionally more ST segment elevation myocardial
infarction (STEMI) patients, and those undergoing
percutaneous coronary intervention, receive optimal
preventive care.
▸ Older patients (>70 years) and those treated in private
hospitals were less likely to receive optimal care.
How might this impact on clinical practice?
▸ Greater focus on in-hospital delivery of preventive care is
needed to provide the essential foundation for lifelong
secondary prevention.
▸ Improved provision of care to a broader range of patients is
needed to ensure equity and access to preventive care
during the inpatient admission.
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